More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer
Posted innews Oncology Urology

More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while significantly increasing the risk of long-term gastrointestinal toxicity.
Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial
Posted innews Oncology Otorhinolaryngology

Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial

A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a new standard for holistic supportive care during intensive oncology treatments.
Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority
Posted innews Oncology Otorhinolaryngology

Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority

A multicenter propensity-matched cohort comparing adjuvant proton beam radiotherapy (PBRT) with intensity-modulated radiotherapy (IMRT) for olfactory neuroblastoma found no definitive differences in local control, recurrence-free survival, overall survival, or clinically meaningful reductions in grade ≥2 radiation toxicities, but estimates were imprecise.
Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice
Posted innews Oncology Otorhinolaryngology

Radiotherapy for Growing Vestibular Schwannomas: Real‑World Tumor Control and What It Means for Practice

An international multicenter cohort of 1,883 patients with radiologically growing vestibular schwannomas treated first‑line with radiotherapy showed a 10‑year tumor control rate of 76.1% (primary definition). Control estimates varied widely by growth definition, underscoring the clinical importance of outcome metrics.
Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial
Posted inOB/GYN & Women's Health Oncology Radiology Specialties

Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial

This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ipsilateral breast events.
Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
Posted innews Oncology Urology

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.
Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT
Posted inClinical Updates Oncology Radiology Specialties

Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT

A randomized trial demonstrates that modified target delineation integrating multimodal MRI and white matter tractography with moderately hypofractionated radiotherapy achieves comparable survival outcomes to standard IMRT while reducing irradiation volumes in high-grade glioma patients.